Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a
single intravenous dose in subjects with major depressive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Naurex, Inc Naurex, Inc, an affiliate of Allergan plc